139 related articles for article (PubMed ID: 17693455)
1. A fold-back single-chain diabody format enhances the bioactivity of an anti-monkey CD3 recombinant diphtheria toxin-based immunotoxin.
Kim GB; Wang Z; Liu YY; Stavrou S; Mathias A; Goodwin KJ; Thomas JM; Neville DM
Protein Eng Des Sel; 2007 Sep; 20(9):425-32. PubMed ID: 17693455
[TBL] [Abstract][Full Text] [Related]
2. Improvement of a recombinant anti-monkey anti-CD3 diphtheria toxin based immunotoxin by yeast display affinity maturation of the scFv.
Wang Z; Kim GB; Woo JH; Liu YY; Mathias A; Stavrou S; Neville DM
Bioconjug Chem; 2007; 18(3):947-55. PubMed ID: 17352456
[TBL] [Abstract][Full Text] [Related]
3. Improved binding of a bivalent single-chain immunotoxin results in increased efficacy for in vivo T-cell depletion.
Thompson J; Stavrou S; Weetall M; Hexham JM; Digan ME; Wang Z; Woo JH; Yu Y; Mathias A; Liu YY; Ma S; Gordienko I; Lake P; Neville DM
Protein Eng; 2001 Dec; 14(12):1035-41. PubMed ID: 11809934
[TBL] [Abstract][Full Text] [Related]
4. Genetic construction and characterization of an anti-monkey CD3 single-chain immunotoxin with a truncated diphtheria toxin.
Ma S; Hu H; Thompson J; Stavrou S; Scharff J; Neville DM
Bioconjug Chem; 1997; 8(5):695-701. PubMed ID: 9327133
[TBL] [Abstract][Full Text] [Related]
5. Effect of pre-existing anti-diphtheria toxin antibodies on T cell depletion levels following diphtheria toxin-based recombinant anti-monkey CD3 immunotoxin treatment.
Matar AJ; Pathiraja V; Wang Z; Duran-Struuck R; Gusha A; Crepeau R; Tasaki M; Sachs DH; Huang CA
Transpl Immunol; 2012 Aug; 27(1):52-4. PubMed ID: 22676970
[TBL] [Abstract][Full Text] [Related]
6. Development of a diphtheria toxin based antiporcine CD3 recombinant immunotoxin.
Wang Z; Duran-Struuck R; Crepeau R; Matar A; Hanekamp I; Srinivasan S; Neville DM; Sachs DH; Huang CA
Bioconjug Chem; 2011 Oct; 22(10):2014-20. PubMed ID: 21866954
[TBL] [Abstract][Full Text] [Related]
7. Expression of an anti-CD3 single-chain immunotoxin with a truncated diphtheria toxin in a mutant CHO cell line.
Liu YY; Gordienko I; Mathias A; Ma S; Thompson J; Woo JH; Neville DM
Protein Expr Purif; 2000 Jul; 19(2):304-11. PubMed ID: 10873546
[TBL] [Abstract][Full Text] [Related]
8. Gene optimization is necessary to express a bivalent anti-human anti-T cell immunotoxin in Pichia pastoris.
Woo JH; Liu YY; Mathias A; Stavrou S; Wang Z; Thompson J; Neville DM
Protein Expr Purif; 2002 Jul; 25(2):270-82. PubMed ID: 12135560
[TBL] [Abstract][Full Text] [Related]
9. Targeted introduction of a diphtheria toxin resistant mutation into the chromosomal EF-2 locus of Pichia pastoris and expression of immunotoxin in the EF-2 mutants.
Liu YY; Woo JH; Neville DM
Protein Expr Purif; 2003 Aug; 30(2):262-74. PubMed ID: 12880776
[TBL] [Abstract][Full Text] [Related]
10. Immunotoxin FN18-CRM9 induces stronger T cell signaling than unconjugated monoclonal antibody FN18.
Hamawy MM; Tsuchida M; Cho CS; Manthei ER; Fechner JH; Knechtle SJ
Transplantation; 2001 Aug; 72(3):496-503. PubMed ID: 11502982
[TBL] [Abstract][Full Text] [Related]
11. Targeting of bivalent anti-ErbB2 diabody antibody fragments to tumor cells is independent of the intrinsic antibody affinity.
Nielsen UB; Adams GP; Weiner LM; Marks JD
Cancer Res; 2000 Nov; 60(22):6434-40. PubMed ID: 11103810
[TBL] [Abstract][Full Text] [Related]
12. Antitumor activity and pharmacokinetics in mice of a recombinant immunotoxin containing a disulfide-stabilized Fv fragment.
Reiter Y; Pai LH; Brinkmann U; Wang QC; Pastan I
Cancer Res; 1994 May; 54(10):2714-8. PubMed ID: 8168102
[TBL] [Abstract][Full Text] [Related]
13. GMP production and characterization of the bivalent anti-human T cell immunotoxin, A-dmDT390-bisFv(UCHT1) for phase I/II clinical trials.
Woo JH; Liu JS; Kang SH; Singh R; Park SK; Su Y; Ortiz J; Neville DM; Willingham MC; Frankel AE
Protein Expr Purif; 2008 Mar; 58(1):1-11. PubMed ID: 18160309
[TBL] [Abstract][Full Text] [Related]
14. Improved stability and yield of a Fv-toxin fusion protein by computer design and protein engineering of the Fv.
Chowdhury PS; Vasmatzis G; Beers R; Lee B; Pastan I
J Mol Biol; 1998 Sep; 281(5):917-28. PubMed ID: 9719644
[TBL] [Abstract][Full Text] [Related]
15. Immunosuppressive properties of anti-CD3 single-chain Fv and diabody.
Le Gall F; Reusch U; Moldenhauer G; Little M; Kipriyanov SM
J Immunol Methods; 2004 Feb; 285(1):111-27. PubMed ID: 14871540
[TBL] [Abstract][Full Text] [Related]
16. Anti-graft-versus-host disease effect of DT390-anti-CD3sFv, a single-chain Fv fusion immunotoxin specifically targeting the CD3 epsilon moiety of the T-cell receptor.
Vallera DA; Panoskaltsis-Mortari A; Jost C; Ramakrishnan S; Eide CR; Kreitman RJ; Nicholls PJ; Pennell C; Blazar BR
Blood; 1996 Sep; 88(6):2342-53. PubMed ID: 8822957
[TBL] [Abstract][Full Text] [Related]
17. Diphtheria-toxin based anti-human CCR4 immunotoxin for targeting human CCR4(+) cells in vivo.
Wang Z; Wei M; Zhang H; Chen H; Germana S; Huang CA; Madsen JC; Sachs DH; Wang Z
Mol Oncol; 2015 Aug; 9(7):1458-70. PubMed ID: 25958791
[TBL] [Abstract][Full Text] [Related]
18. Molecular modification of a recombinant, bivalent anti-human CD3 immunotoxin (Bic3) results in reduced in vivo toxicity in mice.
Vallera DA; Todhunter D; Kuroki DW; Shu Y; Sicheneder A; Panoskaltsis-Mortari A; Vallera VD; Chen H
Leuk Res; 2005 Mar; 29(3):331-41. PubMed ID: 15661270
[TBL] [Abstract][Full Text] [Related]
19. Effect of domain order on the activity of bacterially produced bispecific single-chain Fv antibodies.
Kipriyanov SM; Moldenhauer G; Braunagel M; Reusch U; Cochlovius B; Le Gall F; Kouprianova OA; Von der Lieth CW; Little M
J Mol Biol; 2003 Jun; 330(1):99-111. PubMed ID: 12818205
[TBL] [Abstract][Full Text] [Related]
20. Pharmacology of anti-CD3 diphtheria immunotoxin in CD3 positive T-cell lymphoma trials.
Woo JH; Lee YJ; Neville DM; Frankel AE
Methods Mol Biol; 2010; 651():157-75. PubMed ID: 20686966
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
